retatrutide ly3437943 glp-1 gip glucagon LY3437943, a novel triple glucagon, GIP, and receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism The Road towards Triple Agonists:

A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis1

Irregular dosing can lead to side effects like nausea or digestive discomfort

SLU-PP-332 versus GLP-1 agonists (semaglutide, tirzepatide) GLP-1 analogues are the dominant pharmacological class in obesity in 2024-2025 with clinically documented weight reductions of 15 to 25%

DSIP and Opioid Withdrawal Due to its agonistic activity at opioid receptors, DSIP has been indicated for possible treatment of opioid withdrawal and improvement of withdrawal symptoms

Combining Personalization with Affordable Access PlexusDx compounds semaglutide and tirzepatide through licensed 503A pharmacies, meeting pharmaceutical standards while eliminating brand-name markups